[go: up one dir, main page]

MX2018004542A - Neoepítopos virales y sus usos. - Google Patents

Neoepítopos virales y sus usos.

Info

Publication number
MX2018004542A
MX2018004542A MX2018004542A MX2018004542A MX2018004542A MX 2018004542 A MX2018004542 A MX 2018004542A MX 2018004542 A MX2018004542 A MX 2018004542A MX 2018004542 A MX2018004542 A MX 2018004542A MX 2018004542 A MX2018004542 A MX 2018004542A
Authority
MX
Mexico
Prior art keywords
neoepitopes
viral
antiviral
analysis
integrated
Prior art date
Application number
MX2018004542A
Other languages
English (en)
Other versions
MX387275B (es
Inventor
Nguyen Andrew
Charles Benz Stephen
Zachary Sanborn John
Original Assignee
Nantomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics Llc filed Critical Nantomics Llc
Publication of MX2018004542A publication Critical patent/MX2018004542A/es
Publication of MX387275B publication Critical patent/MX387275B/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Primary Health Care (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Library & Information Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)

Abstract

Los tratamientos antivirales/anticáncer contemplados comprenden el análisis de neoepítopos de ADN viral que se ha integrado en el genoma del anfitrión, y el diseño de agentes inmunoterapéuticos contra dichos neoepítopos.
MX2018004542A 2015-10-12 2016-10-12 Neoepítopos virales y sus usos MX387275B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562240471P 2015-10-12 2015-10-12
PCT/US2016/056594 WO2017066290A1 (en) 2015-10-12 2016-10-12 Viral neoepitopes and uses thereof

Publications (2)

Publication Number Publication Date
MX2018004542A true MX2018004542A (es) 2018-11-22
MX387275B MX387275B (es) 2025-03-18

Family

ID=57882798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004542A MX387275B (es) 2015-10-12 2016-10-12 Neoepítopos virales y sus usos

Country Status (10)

Country Link
US (3) US10339274B2 (es)
EP (1) EP3362929B1 (es)
JP (1) JP6991967B2 (es)
KR (1) KR102770755B1 (es)
CN (1) CN108604257B (es)
AU (1) AU2016338947B2 (es)
CA (1) CA3003304A1 (es)
IL (1) IL258682B (es)
MX (1) MX387275B (es)
WO (1) WO2017066290A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12080382B2 (en) 2015-10-12 2024-09-03 Nantomics, Llc Viral neoepitopes and uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
US10776966B2 (en) * 2017-04-28 2020-09-15 Oracle International Corporation Graph processing system that allows flexible manipulation of edges and their properties during graph mutation
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
WO2020022898A2 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
WO2020185411A1 (en) 2019-03-08 2020-09-17 Nantomics, Llc System and method for variant calling
KR102425492B1 (ko) * 2020-04-27 2022-07-26 한림대학교 산학협력단 Sars-cov-2 바이러스에 대한 에피토프 기반 펩타이드 백신의 개발 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518569C (en) 2003-03-10 2011-11-15 Expression Pathology, Inc. Liquid tissue preparation from histopathologically processed biological samples, tissues and cells
ES2439490T3 (es) * 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
CN102197144A (zh) * 2008-08-22 2011-09-21 诺瓦提斯公司 Cox-2抑制剂用于治疗不携带与肝脏毒性相关的hla等位基因的患者中cox-2依赖性疾病的用途
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2011143656A2 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
CA2797645C (en) 2010-05-25 2020-09-22 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
RU2670745C9 (ru) * 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
DK2742133T3 (en) * 2011-08-12 2017-12-04 Oncotherapy Science Inc MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THESE
CA2849624C (en) * 2011-09-23 2021-05-25 Oxford Nanopore Technologies Limited Analysis of a polymer comprising polymer units
EP2802347B1 (en) * 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
NO2802607T3 (es) * 2012-01-13 2018-03-03
JP2015533473A (ja) * 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
CA3137846A1 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
CN103320522B (zh) * 2013-07-16 2016-03-30 深圳华大基因研究院 确定人宫颈癌样本基因组中hpv整合位点的方法和系统
JP2015035212A (ja) * 2013-07-29 2015-02-19 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ターゲットシークエンシングパネルから変異を見つける方法
AU2014324729B2 (en) 2013-09-26 2019-08-22 Five3 Genomics, Llc Systems, methods, and compositions for viral-associated tumors
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
SG10201805674YA (en) * 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
CA2987239A1 (en) * 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
WO2017066290A1 (en) 2015-10-12 2017-04-20 Nantomics, Llc Viral neoepitopes and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12080382B2 (en) 2015-10-12 2024-09-03 Nantomics, Llc Viral neoepitopes and uses thereof

Also Published As

Publication number Publication date
EP3362929A1 (en) 2018-08-22
EP3362929A4 (en) 2019-06-19
JP6991967B2 (ja) 2022-01-13
US20240321392A1 (en) 2024-09-26
CN108604257A (zh) 2018-09-28
US12080382B2 (en) 2024-09-03
KR20180087248A (ko) 2018-08-01
KR102770755B1 (ko) 2025-02-21
IL258682B (en) 2022-03-01
JP2018536225A (ja) 2018-12-06
CA3003304A1 (en) 2017-04-20
AU2016338947A1 (en) 2018-05-10
CN108604257B (zh) 2022-12-13
US20190287656A1 (en) 2019-09-19
EP3362929B1 (en) 2020-08-12
AU2016338947B2 (en) 2020-06-04
US10339274B2 (en) 2019-07-02
US20170032103A1 (en) 2017-02-02
HK1258093A1 (en) 2019-11-01
MX387275B (es) 2025-03-18
WO2017066290A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
MX2018004542A (es) Neoepítopos virales y sus usos.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
BR112018016450A2 (pt) composições intensificadoras de vcn e métodos de uso das mesmas
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MX2021006635A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas.
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
ECSP17073743A (es) Moduladores de k-ras
MX384024B (es) Peptidos macrociclicos utiles como inmunomoduladores.
EP3368656A4 (en) TARGETED CANCER THERAPY
MX2021006053A (es) Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
LT3119437T (lt) Genų terapija, skirta pigmentiniam retinitui
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
BR112018003019A2 (pt) vacinas terapêuticas contra hpv18
MY181693A (en) Dual quencher probes
MX2016017382A (es) Metodos para preparar analogos de nucleotido sustituidos.
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX383931B (es) Compuestos de aza-piridona y usos de estos.
CL2016002839A1 (es) Derivados de carboxamida